 Larimar Therapeutics Inc NASDAQ: LRMR has executed a securities purchase agreement to raise gross proceeds of approximately 95 million in a private placement. The proceeds will be used to support the clinical development of CTI-1601, additional RD, and working capital, and general corporate purposes. 